Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcus Schmidt

Showing results (291-300 of 326) with videos related to

Pageof 33
Sort By:
Breast (Edinburgh, Scotland)|October 12, 2022
Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 studyMattea Reinisch, Michael Untch, Rolf Mahlberg, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 20, 2023
Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growthMagdalena Keller, Katharina Rohlf, Annika Glotzbach, et al.
Nature Communications|March 15, 2016
Superconductivity in Weyl semimetal candidate MoTe2Yanpeng Qi, Pavel G Naumov, Mazhar N Ali, et al.
NPJ Breast Cancer|July 30, 2024
GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancerVolker Möbus, Hans-Joachim Lück, Ekkehart Ladda, et al.
JAMA|October 8, 2009
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifenWerner Schroth, Matthew P Goetz, Ute Hamann, et al.
JAMA Oncology|July 15, 2021
Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical TrialR Charles Coombes, Holly Tovey, Lucy Kilburn, et al.
Virchows Archiv : an International Journal of Pathology|February 29, 2012
Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assayCarsten Denkert, Ralf Kronenwett, Werner Schlake, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2011
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factorsMartin Filipits, Margaretha Rudas, Raimund Jakesz, et al.
International Journal of Cancer|January 18, 2019
LIPG-promoted lipid storage mediates adaptation to oxidative stress in breast cancerCristina Cadenas, Sonja Vosbeck, Karolina Edlund, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2021
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)Volker Möbus, Hans-Joachim Lück, Ekkehart Ladda, et al.
Pageof 33

Showing results (291-300 of 326) with videos related to

Sort By:
Pageof 33
Breast (Edinburgh, Scotland)|October 12, 2022
Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 studyMattea Reinisch, Michael Untch, Rolf Mahlberg, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 20, 2023
Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growthMagdalena Keller, Katharina Rohlf, Annika Glotzbach, et al.
Nature Communications|March 15, 2016
Superconductivity in Weyl semimetal candidate MoTe2Yanpeng Qi, Pavel G Naumov, Mazhar N Ali, et al.
NPJ Breast Cancer|July 30, 2024
GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancerVolker Möbus, Hans-Joachim Lück, Ekkehart Ladda, et al.
JAMA|October 8, 2009
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifenWerner Schroth, Matthew P Goetz, Ute Hamann, et al.
JAMA Oncology|July 15, 2021
Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical TrialR Charles Coombes, Holly Tovey, Lucy Kilburn, et al.
Virchows Archiv : an International Journal of Pathology|February 29, 2012
Decentral gene expression analysis for ER+/Her2- breast cancer: results of a proficiency testing program for the EndoPredict assayCarsten Denkert, Ralf Kronenwett, Werner Schlake, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2011
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factorsMartin Filipits, Margaretha Rudas, Raimund Jakesz, et al.
International Journal of Cancer|January 18, 2019
LIPG-promoted lipid storage mediates adaptation to oxidative stress in breast cancerCristina Cadenas, Sonja Vosbeck, Karolina Edlund, et al.
European Journal of Cancer (Oxford, England : 1990)|August 27, 2021
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)Volker Möbus, Hans-Joachim Lück, Ekkehart Ladda, et al.
Pageof 33